Cargando…
Parkinson’s disease: carbidopa, nausea, and dyskinesia
When l-dopa use began in the early 1960s for the treatment of Parkinson’s disease, nausea and reversible dyskinesias were experienced as continuing side effects. Carbidopa or benserazide was added to l-dopa in 1975 solely to control nausea. Subsequent to the increasing use of carbidopa has been the...
Autores principales: | Hinz, Marty, Stein, Alvin, Cole, Ted |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238750/ https://www.ncbi.nlm.nih.gov/pubmed/25484598 http://dx.doi.org/10.2147/CPAA.S72234 |
Ejemplares similares
-
The Parkinson’s disease death rate: carbidopa and vitamin B6
por: Hinz, Marty, et al.
Publicado: (2014) -
Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Retraction]
Publicado: (2021) -
Parkinson’s Disease: Carbidopa, Nausea, and Dyskinesia [Expression of Concern]
Publicado: (2020) -
Parkinson’s disease-associated melanin steal
por: Hinz, Marty, et al.
Publicado: (2014) -
Parkinson’s disease managing reversible neurodegeneration
por: Hinz, Marty, et al.
Publicado: (2016)